El Gohary2017
El Gohary2017
El Gohary2017
DOI 10.1007/s00383-017-4196-y
REVIEW ARTICLE
Introduction
Hypertrophic pyloric stenosis (HPS) is considered one of the
hallmark pediatric surgical diseases. It is the most common
surgical condition causing nonbilious emesis in infancy, and
Electronic supplementary material The online version of this
article (doi:10.1007/s00383-017-4196-y) contains supplementary
material, which is available to authorized users.
* Andrew J. Murphy
[email protected]
1
History
Hypertrophic pyloric stenosis was first documented by
Harald Hirschsprung, a Danish Pediatrician, in 1888 in
two post-mortem cases [3]. Treatment of pyloric stenosis
in the late nineteenth and early twentieth centuries broadly
entailed three types of surgical interventions: dilatation of
the pylorus, pyloroplasty, and gastroenterostomy [4]. Dilatation of the pyloric
orifice was first described by Professor Loreta, of Bologna, Italy, in 1882 on
adult patients [5].
This was later adopted in pediatric patients with the pyloric
sphincter forcibly dilated using either one or two fingers,
after gaining access to the distal stomach through an incision, or using a
mechanical Hegar dilator [4] (Fig. 1). However, “Loreta’s operation” was later
abandoned due to the
unsatisfactory results with high recurrences and fatal peritonitis due to pyloric
rupture. Dr. Clinton Thomas Dent, an
English surgeon, later performed the first successful pyloroplasty 1902, which
involved incising the pylorus muscle
13
Vol.:(0123456789)
Pediatr Surg Int
Diagnosis
Epidemiology
The incidence of HPS is 2–4 per 1000 live births with geographical variation [2].
It is rare or absent in the developing
world and in sub-Saharan Africa, thus it is considered as a
“Western disease” [10, 11]. This strongly suggests an environmental factor. It has
a strongly male predilection, occurring often in first-born males, with a male to
female ratio
6:1 and the median age for presentation is 40 days old [12].
HPS is more common in Whites than Asians, Hispanics or
Blacks. The incidence in Whites is 2.4 per 1000 live births,
1.8 in Hispanics, 0.7 in Blacks, and 0.6 in Asians [13].
Clinical presentation
Classically, patients with pyloric stenosis present with
postprandial, projectile, nonbilious emesis and are typically
hungry after vomiting. This must be differentiated from
the more common cause of vomiting in infancy, gastroesophageal reflux (GER), which
is a physiologic self-limiting
condition that usually resolves by 6 to 12 months of age.
Patients with GER typically regurgitate or “spit up” their
feeds. Significant delay in diagnosing HPS can lead to protracted vomiting which
can eventually lead to blood-tinged
emesis from gastritis. In the past, before the advent of ultrasound, patients often
became so emaciated that the pyloric
‘olive’, a term which describes how the palpable hypertrophied pylorus feels on
physical examination, became visible
on the abdominal wall along with visible gastric peristalsis
13
Pediatr Surg Int
Postoperative feeding
The optimum feeding regimen is yet to be determined with
feeding strategies varying widely among different institutions. In the past, it was
believed that fasting up to 24 h
postoperatively would decrease the number of emesis based
on early gastric motility studies demonstrating normal gastric peristalsis
returning 24 h after surgery [29, 30]. However, that dogma has changed recently
with most centers
instituting ad libitum postoperative feeding as the enteral
feeding of choice [31]. A recent meta-analysis demonstrated
that ad libitum feeding decreased the length of stay and
decreased time to achieve full enteral feeding when compared to a structured
feeding regimen [31]. The variation in
feeding protocol is based on a surgeon’s preference and the
fear for the development of postoperative emesis. Regardless of the postoperative
feeding regimen chosen, postoperative emesis will occur [23, 31–33]. One of the
important
aspects of the postoperative managements of HPS patients
is parental education regarding the self-limiting nature of
postoperative vomiting.
Intraoperative and perioperative complications
The key intraoperative complications associated with
pyloromyotomy are mucosal perforation and incomplete
myotomy. Mucosal perforation most commonly occurs
at the duodenal end of the pyloric incision because the
13
Pediatr Surg Int
mucosal lining balloons out quite rapidly and the serosal surface of the pylorus
substantially thins as it transitions to the duodenal bulb. Intraoperative
recognition of
mucosal perforation is critical, as unrecognized perforation can lead to
postoperative peritonitis, sepsis, and
death. Limited perforation can be repaired by simple
suturing, while more extensive perforations should be
repaired by completely closing the pyloromyotomy, rotating the pylorus ninety
degrees, and repeating the pyloromyotomy at this alternate location. Incomplete
pyloromyotomy is most often caused by insufficient disruption
of the muscular fibers on the gastric end of the pyloric
incision. Incomplete pyloromyotomy will cause persistent
vomiting postoperatively and should be considered when
these symptoms persist beyond one week. The diagnosis (or exclusion) of incomplete
myotomy is most readily
made by an upper gastrointestinal study performed when
postoperative vomiting persists for more than seven days
postoperatively [28]. A study suspicious of incomplete
myotomy will reveal delayed gastric emptying of contrast
and a “string sign” as contrast transits the persistently
narrowed pylorus [34]. As mentioned above, vomiting
may persist postoperatively for up to one week despite
adequate pyloromyotomy due to postoperative pyloric
edema or gastric atony due to chronic obstruction [35].
Non-operative management
The only accepted non-operative management for the
treatment of HPS is the use of atropine sulfate. This medical management is usually
reserved for patients who are
deemed unfit to undergo general anesthesia due to severe
medical co-morbidities. Atropine is a parasympatholytic,
due its competitive, reversible antagonistic binding to the
muscarinic acetylcholine receptors. It inhibits peristalsis
and therefore reduces muscular spasms that are thought
to lead to muscular hypertrophy of HPS [36]. It is also a
very strong inhibitor of meal-induced gastric acid secretion [37]. This presumably
will mitigate the acidic environment and thus prevent pyloric sphincter
contraction. It
has also been used successfully to treat incomplete pyloromyotomy as a ‘rescue
therapy’ [34]. Takeuchi et al. [36]
revealed in their series of 188 patients treated initially
with atropine, (intravenous form, n = 80; oral form, n = 8),
they had an overall success rate of 78.9% (142/180). The
reported median number of days needed for successful
medical treatment is between 12 and 14 days [36] with
most recommending intravenous dose of 0.06 mg/kg/day.
Etiology
The exact cause of the postnatal pyloric muscle thickening
characteristic of HPS is unclear, but it is mostly likely multifactorial. Duodenal
exposure to acid is known to be a potent
stimulus of pyloric sphincter contraction. Furthermore, high
levels of gastrin have been documented after birth in some
patients with pyloric stenosis. Thus, the gastrin theory postulates that the high
gastrin levels will promote hyperacidity,
which stimulates the cycle of pyloric sphincter contraction
and results in muscle hypertrophy [38]. The acid hypersecretion phenomenon has been
reported by Heine et al. [39], who
documented higher histamine-induced gastric acid secretion
in infants with pyloric stenosis before and one week after
pyloromyotomy. In addition, animal studies have induced
pyloric stenosis in newborn dogs after the administration of
maternal pentagastrin shortly before birth [40]. The hypothesis of work-induced
hypertrophy of the pylorus muscle is
further supported by the association between pyloric stenosis and the use of
erythromycin and azithromycin. Both
macrolide antibiotics are known to act as prokinetic agents
due to their stimulation of motilin receptors in the antrum
and pylorus of the stomach, which promotes peristalsis and
gastric emptying [41]. A sevenfold increase in the incidence
of HPS was reported among newborns that received the antibiotic erythromycin for
post-exposure pertussis prophylaxis
[42]. More recently, a cohort study found a strong association between HPS and
infants receiving macrolide antibiotics, especially if received within the first
two weeks of
life, resulting in a 30-fold increased risk of HPS [43, 44].
Infant consumption from two weeks to four months of age
or maternal consumption during the first two weeks of life
also resulted in a threefold increased risk [43]. The strong
male predominance has remained a mystery, but one clue
is the documentation of preterm male babies having more
acid compared to matched females [45]. Another interesting observation is that
bottle-feeding appears to be independently associated with HPS with a 4.6-fold
increase risk
compared to infants who were breastfed [46]. Other theories include deficiency of
nitric oxide synthase containing
neurons within the thickened pylorus [47]. Nitric oxide is a
major cellular signaling molecule produced by endothelial
cells that relaxes smooth muscle and acts as a major vasodilator. Hence, the
abnormal pyloric innervation is postulated to result in inadequate relaxation of
the pylorus muscle
leading to hypertrophy [48]. This led the investigators to
postulate the gene for nitric oxide synthetase, NOS1, as a
candidate gene for HPS [49].
Genetic inheritance for HPS is complex and multifactorial. There is increased
concordance between monozygotic
twins, when compared to dizygotic twins, and patients with
pyloric stenosis occasionally have a family history of this
condition. Pyloric stenosis is associated with several genetic
13
Pediatr Surg Int
Conclusion
HPS is one of most frequently treated pediatric surgical conditions, but continues
to have an incompletely understood
etiology. Early diagnosis by physical exam or ultrasound
and appropriate fluid resuscitation followed by pyloromyotomy has transformed HPS
from a lethal condition into
a readily diagnosed and treated malady with nearly 100%
survival. Despite various proposed genetic etiologies, the
widespread geographical and ethnic variations are likely
indicators of a mixed environmental and genetic explanation
for this disease. While the precise etiology remains elusive,
work-induced hypertrophy of the pylorus muscle seems to be
the most plausible, unifying physiologic explanation. This
hypothesis is strongly supported by a recent Danish nationwide cohort study
demonstrating a 30-fold increased risk of
developing HPS with use of prokinetic macrolide antibiotics
in early infancy [43]. This hypothesis is further supported
by the success of atropine sulfate, which reduces muscular
spasms of the pylorus, as a medical treatment for HPS and a
rescue treatment for incomplete pyloromyotomy. Thus, the
administration of macrolide antibiotics to infants during the
first few months of life should be discouraged, unless the
treatment benefits outweigh the risk.
Acknowledgements This research received no specific grant from
any funding agency in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Ethical approval This article does not contain any studies with
human participants performed by any of the authors.
Conflict of interest The authors declare no conflict of interest.
References
1. Ramstedt C (1912) Zur operation der angeborenen pylorus stenose. Med Klin
8:1702–1705
2. To T, Wajja A, Wales PW, Langer JC (2005) Population demographic indicators
associated with incidence of pyloric stenosis.
Arch Pediatr Adolesc Med 159:520–525
13
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, Correa A,
Hall S, Erickson JD (1999) Infantile hypertrophic pyloric stenosis after pertussis
prophylaxis with erythromcyin: a case review and cohort study. Lancet 354:2101–2105
43. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz
LJ, Wohlfahrt J, Melbye M (2014) Use of macrolides in mother
and child and risk of infantile hypertrophic pyloric stenosis:
nationwide cohort study. BMJ 348:g1908
44. Eberly MD, Eide MB, Thompson JL, Nylund CM (2015)
Azithromycin in early infancy and pyloric stenosis. Pediatrics
135:483–488
45. Ames MD (1960) Gastric acidity in the first ten days of life of the
prematurely born baby. Am J Dis Child 100:252–256
46. Krogh C, Biggar RJ, Fischer TK, Lindholm M, Wohlfahrt J, Melbye M (2012)
Bottle-feeding and the risk of pyloric stenosis. Pediatrics 130:e943-949
47. Piotrowska AP, Solari V, Puri P (2003) Distribution of heme oxygenase-2 in
nerves and interstitial cells of Cajal in the normal
pylorus and in infantile hypertrophic pyloric stenosis. Arch Pathol
Lab Med 127:1182–1186
48. Oue T, Puri P (1999) Smooth muscle cell hypertrophy versus
hyperplasia in infantile hypertrophic pyloric stenosis. Pediatr Res
45:853–857
49. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC
(1993) Targeted disruption of the neuronal nitric oxide synthase
gene. Cell 75:1273–1286
50. Peeters B, Benninga MA, Hennekam RC (2012) Infantile hypertrophic pyloric
stenosis–genetics and syndromes. Nat Rev Gastroenterol Hepatol 9:646–660
51. Krogh C, Fischer TK, Skotte L, Biggar RJ, Oyen N, Skytthe
A, Goertz S, Christensen K, Wohlfahrt J, Melbye M (2010)
Familial aggregation and heritability of pyloric stenosis. Jama
303:2393–2399
52. Pedersen RN, Garne E, Loane M, Korsholm L, Husby S, Group
EW (2008) Infantile hypertrophic pyloric stenosis: a comparative study of incidence
and other epidemiological characteristics in seven European regions. J Maternal
Fetal Neonatal Med
21:599–604
53. Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, Bejjani BA, Ou
Z, Wiszniewska J, Driscoll DJ, Maisenbacher MK et al (2009)
Genomic and genic deletions of the FOX gene cluster on 16q24.1
and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other
malformations. Am J Hum Genet 84:780–791
54. Everett KV, Ataliotis P, Chioza BA, Shaw-Smith C, Chung
E.M.K. (2017) A novel missense mutation in the transcription
factor FOXF1 cosegregating with infantile hypertrophic pyloric
stenosis in the extended pedigree linked to IHPS5 on chromosome
16q24. Pediatr Res 81:632–638
13